IDEXX Laboratories, Inc. (IDXX) Financials
IDXX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 3.4 billion | 1.8 billion |
2023-12-31 | 3.3 billion | 1.8 billion |
2023-09-30 | 3.1 billion | 1.8 billion |
2023-06-30 | 2.9 billion | 1.8 billion |
IDXX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 168.3 million | 14.4 million |
2023-12-31 | 217.3 million | 15.2 million |
2023-09-30 | 238.3 million | 15.2 million |
2023-06-30 | 172.8 million | 15.4 million |
IDXX Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2024-03-31 | 235.6 million |
2023-12-31 | 194.5 million |
2023-09-30 | 212.2 million |
2023-06-30 | 224.2 million |
IDXX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 397.4 million | - | 123.2 million |
2023-12-31 | 453.9 million | - | 119.5 million |
2023-09-30 | 331.7 million | - | 121.4 million |
2023-06-30 | 132.8 million | 696.8 million | 117.0 million |
IDXX Shares Outstanding
IDXX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 30.3 million | 52.6 million | 92.0 million | 149.5 million |
2023-12-31 | 32.6 million | 51.8 million | 87.0 million | 142.0 million |
2023-09-30 | 34.1 million | 48.0 million | 89.0 million | 135.7 million |
2023-06-30 | 27.5 million | 46.5 million | 89.7 million | 140.5 million |
IDXX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 964.1 million | 371.0 million |
2023-12-31 | 901.6 million | 375.4 million |
2023-09-30 | 915.5 million | 367.5 million |
2023-06-30 | 943.6 million | 370.8 million |
IDXX
Price: $480.60
52 week price:
Payout Ratio Range:
Earnings Per Share: 10.04 USD
P/E Ratio: 57.86
Exchange: NMS
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 353885
Ebitda: 120.9 millionMarket Capitalization: 39.3 billion